rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Heals Haloperidol-Induced Stomach Damage Through Dopamine Pathway Interaction

RPEP-006512001Bilic, I; Zoricic, I; Anic, T; Separovic, J; Stancic-Rokotov, D; Mikus, D; Buljat, G; Ivankovic, D; Aralica, G; Prkacin, I; Perovic, D; Mise, S; Rotkvic, I; Petek, M; Rucman, R; Seiwerth, S; Sikiric, P
Animal StudyPreliminary evidence
The takeaway

BPC-157 and omeprazole healed haloperidol-induced gastric lesions while atropine and lansoprazole did not, confirming BPC-157's healing involves the central dopamine system rather than just acid suppression.

Dopamine, not acid

BPC-157 healed haloperidol lesions that acid-blocking drugs couldn't touch — confirming its mechanism is dopaminergic, not acid-related

What the researchers found

BPC-157, omeprazole, and bromocriptine healed haloperidol-induced gastric lesions, while atropine, lansoprazole, and cimetidine failed, demonstrating the lesions are dopamine-mediated and BPC-157 acts through dopaminergic mechanisms.

Why it matters

The selective healing pattern provides the strongest evidence yet that BPC-157 works through dopamine system interaction, not just general cytoprotection or acid reduction.

How the study worked

Animal study in rats. Haloperidol-induced gastric lesions treated with BPC-157, omeprazole, bromocriptine, atropine, lansoprazole, or cimetidine. Lesion healing assessed. Prostaglandin and dopamine pathway contributions dissected.

What this study cannot tell us

Animal study. The specific dopamine receptor subtypes involved were not determined. Omeprazole's healing may work through a non-acid mechanism in this model.

How to read the evidence

Preliminary animal evidence with clear selective healing pattern providing mechanistic insight through comparative drug testing.

When this study was published

Published in 2001. BPC-157's dopamine system interaction has been further characterized in subsequent studies.

The bigger picture

BPC-157's dopaminergic mechanism distinguishes it from all conventional gastroprotective drugs. This unique mechanism explains why it heals damage that acid-reducing drugs cannot.

Questions still open

  • Which dopamine receptor subtype does BPC-157 interact with?
  • Could BPC-157 prevent GI side effects in all patients taking antipsychotics?
  • Is BPC-157's dopamine interaction direct or indirect?

Common questions

Why can't regular stomach drugs heal these ulcers?
Haloperidol causes stomach damage through the dopamine system, not excess acid. Acid-blocking drugs like lansoprazole and cimetidine address the wrong mechanism. BPC-157 heals them because it works through the dopamine system.
Is this relevant for people on antipsychotics?
Potentially very relevant. Antipsychotic drugs work by blocking dopamine and commonly cause GI problems. BPC-157's ability to heal dopamine-related gut damage suggests it could protect patients' stomachs during antipsychotic therapy.

Read the original research

Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.

Life sciences, 68(16), 1905-12

View on PubMed ↗

Citation

Bilic, I; Zoricic, I; Anic, T; Separovic, J; Stancic-Rokotov, D; Mikus, D; Buljat, G; Ivankovic, D; Aralica, G; Prkacin, I; Perovic, D; Mise, S; Rotkvic, I; Petek, M; Rucman, R; Seiwerth, S; Sikiric, P. (2001). Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.. Life sciences, 68(16), 1905-12.